NASDAQ:ATRA - Atara Biotherapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$23.47 -0.52 (-2.17 %)
(As of 05/21/2019 08:31 AM ET)
Previous Close$23.99
Today's Range$23.12 - $24.14
52-Week Range$23.12 - $54.45
Volume412,866 shs
Average Volume558,753 shs
Market Capitalization$1.09 billion
P/E RatioN/A
Dividend YieldN/A
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, and autoimmune and viral diseases, including ATA2271 for mesothelin; ATA2321 for acute myeloid leukemia; and ATA2431 and ATA3219 for B-cell lymphomas, as well as ATA188 and ATA190 that are in Phase I clinical trials for the treatment of multiple sclerosis. In addition, it is developing ATA621 against the BK and JC viruses; ATA368 for patients with human papillomavirus and associated cancers; ATA520 to treat Wilms tumor 1; and ATA230 against cytomegalovirus and related diseases. The company has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in South San Francisco, California.

Receive ATRA News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:ATRA



Sales & Book Value

Annual SalesN/A
Book Value$6.13 per share


Net Income$-230,700,000.00


Market Cap$1.09 billion
Next Earnings Date8/7/2019 (Estimated)

Atara Biotherapeutics (NASDAQ:ATRA) Frequently Asked Questions

What is Atara Biotherapeutics' stock symbol?

Atara Biotherapeutics trades on the NASDAQ under the ticker symbol "ATRA."

How were Atara Biotherapeutics' earnings last quarter?

Atara Biotherapeutics Inc (NASDAQ:ATRA) posted its quarterly earnings results on Thursday, May, 9th. The biotechnology company reported ($1.44) earnings per share for the quarter, topping the consensus estimate of ($1.48) by $0.04. View Atara Biotherapeutics' Earnings History.

When is Atara Biotherapeutics' next earnings date?

Atara Biotherapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August 7th 2019. View Earnings Estimates for Atara Biotherapeutics.

What price target have analysts set for ATRA?

5 brokerages have issued 12-month price objectives for Atara Biotherapeutics' shares. Their predictions range from $23.00 to $62.00. On average, they anticipate Atara Biotherapeutics' share price to reach $43.3333 in the next year. This suggests a possible upside of 84.6% from the stock's current price. View Analyst Price Targets for Atara Biotherapeutics.

What is the consensus analysts' recommendation for Atara Biotherapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atara Biotherapeutics in the last year. There are currently 1 sell rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Atara Biotherapeutics.

What are Wall Street analysts saying about Atara Biotherapeutics stock?

Here are some recent quotes from research analysts about Atara Biotherapeutics stock:
  • 1. According to Zacks Investment Research, "Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company's lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California. " (4/30/2019)
  • 2. William Blair analysts commented, "We view the results as very promising given the high efficacy and very favorable safety profile, with no evidence of on-target, off-tumor toxicity of the CAR-T therapy . Given the strong expression of mesothelin across several tumor types, including mesothelioma (90%-plus), lung adenocarcinoma (60%-plus), triple negative breast cancer (TNBC, 35%), and pancreatic cancer (80%), the opportunity for a mesothelin- CAR-T therapy with a strong safety profile is significant." (4/1/2019)
  • 3. Mizuho analysts commented, "We note that this is not the first time the company has put an ATM in place." (2/26/2019)

Has Atara Biotherapeutics been receiving favorable news coverage?

News stories about ATRA stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Atara Biotherapeutics earned a news sentiment score of -1.1 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the stock's share price in the near term.

Who are some of Atara Biotherapeutics' key competitors?

What other stocks do shareholders of Atara Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Atara Biotherapeutics investors own include Crispr Therapeutics (CRSP), Micron Technology (MU), Portola Pharmaceuticals (PTLA), Editas Medicine (EDIT), Exelixis (EXEL), AbbVie (ABBV), Alibaba Group (BABA), Heron Therapeutics (HRTX), Johnson & Johnson (JNJ) and Amgen (AMGN).

Who are Atara Biotherapeutics' key executives?

Atara Biotherapeutics' management team includes the folowing people:
  • Dr. Isaac E. Ciechanover, Pres, CEO & Director (Age 48)
  • Mr. Joseph Newell, Exec. VP & Chief Technical Operations Officer (Age 49)
  • Dr. Derrell D. Porter, Sr. VP & Global Commercial Head (Age 48)
  • Mr. Utpal Koppikar, Chief Financial Officer
  • Dr. Christopher M. Haqq, Exec. VP of R&D & Chief Scientific Officer (Age 53)

Who are Atara Biotherapeutics' major shareholders?

Atara Biotherapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (13.86%), Redmile Group LLC (9.68%), BlackRock Inc. (7.52%), JPMorgan Chase & Co. (4.14%), Eagle Asset Management Inc. (3.34%) and Neuberger Berman Group LLC (2.82%). Company insiders that own Atara Biotherapeutics stock include Carol Giltner Gallagher, Christopher Haqq, Derrell Porter, Gad Soffer, Heather D Turner, Isaac E Ciechanover, Joe Newell, Joel S Marcus, John Mcgrath, Matthew K Fust, Mitchall G Clark and Utpal Koppikar. View Institutional Ownership Trends for Atara Biotherapeutics.

Which institutional investors are selling Atara Biotherapeutics stock?

ATRA stock was sold by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, Morgan Stanley, Citigroup Inc., Eagle Asset Management Inc., Carillon Tower Advisers Inc., Goldman Sachs Group Inc., BlackRock Inc. and Parametric Portfolio Associates LLC. Company insiders that have sold Atara Biotherapeutics company stock in the last year include Carol Giltner Gallagher, Christopher Haqq, Derrell Porter, Isaac E Ciechanover, Joe Newell and Joel S Marcus. View Insider Buying and Selling for Atara Biotherapeutics.

Which institutional investors are buying Atara Biotherapeutics stock?

ATRA stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Maverick Capital Ltd., JPMorgan Chase & Co., Federated Investors Inc. PA, Wasatch Advisors Inc., Redmile Group LLC, Pacific Heights Asset Management LLC and Marshall Wace North America L.P.. View Insider Buying and Selling for Atara Biotherapeutics.

How do I buy shares of Atara Biotherapeutics?

Shares of ATRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Atara Biotherapeutics' stock price today?

One share of ATRA stock can currently be purchased for approximately $23.47.

How big of a company is Atara Biotherapeutics?

Atara Biotherapeutics has a market capitalization of $1.09 billion. The biotechnology company earns $-230,700,000.00 in net income (profit) each year or ($5.27) on an earnings per share basis. Atara Biotherapeutics employs 311 workers across the globe.

What is Atara Biotherapeutics' official website?

The official website for Atara Biotherapeutics is

How can I contact Atara Biotherapeutics?

Atara Biotherapeutics' mailing address is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-278-8930.

MarketBeat Community Rating for Atara Biotherapeutics (NASDAQ ATRA)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  338 (Vote Outperform)
Underperform Votes:  240 (Vote Underperform)
Total Votes:  578
MarketBeat's community ratings are surveys of what our community members think about Atara Biotherapeutics and other stocks. Vote "Outperform" if you believe ATRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/21/2019 by Staff

Featured Article: Golden Cross

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel